In this regard, decitabine leads to the selective activation of specific genes only in tumor cells opening to the intriguing hypothesis that DNMT inhibitors may increase the therapeutic index of specific antitumor strategies consenting of targeting the gene products differentially expressed in tumor cells [169]. The gene discussed is DNMT1; the disease is neoplasm.